Loading…
GT Biopharma, Inc. is projected to decline to $0.3678 by 2027, a -13% move from its current price of $0.425. GTBP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.4035 | $0.4247 | $0.447 | -0.07% |
| Jul 14 | $0.3948 | $0.4244 | $0.4563 | -0.13% |
| Jul 15 | $0.3882 | $0.4242 | $0.4635 | -0.20% |
| Jul 16 | $0.3826 | $0.4239 | $0.4695 | -0.27% |
| Jul 17 | $0.3778 | $0.4236 | $0.4749 | -0.33% |
| Jul 18 | $0.3735 | $0.4233 | $0.4798 | -0.40% |
| Jul 19 | $0.3695 | $0.423 | $0.4843 | -0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3695 | $0.423 | $0.4843 | -0.46% |
| Week 2 | $0.3477 | $0.4211 | $0.5099 | -0.92% |
| Week 3 | $0.3315 | $0.4191 | $0.5299 | -1.38% |
| Week 4 | $0.3182 | $0.4172 | $0.5469 | -1.84% |
| Week 5 | $0.3068 | $0.4152 | $0.562 | -2.30% |
| Week 6 | $0.2967 | $0.4133 | $0.5758 | -2.75% |
| Week 7 | $0.2876 | $0.4114 | $0.5886 | -3.20% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company that engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms.
It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
GT Biopharma, Inc. (GTBP) operates in the Healthcare sector. The current price is $0.425 and the market capitalization is $15.33M. The stock is ranked 4959.
Forecasts show a path of price movement over the next several years, with the 2026 average price at $0.425 and a trajectory that includes bullish years such as 2029 (avg $0.5324) and 2030 (avg $0.5475), continuing to 2040 (avg $0.8062) and 2050 (avg $1.66). This reflects a long-run growth potential under varying market conditions.
A major floor 36.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.4% away) — a key level to hold.
The nearest ceiling, 20.9% above — a clean break opens room to run.
A major ceiling 29.5% above — clearing it would confirm fresh momentum.
Key GTBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GTBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.458 | Sell | $0.4501 | Sell |
| MA 10 | $0.4616 | Sell | $0.4571 | Sell |
| MA 20 | $0.4622 | Sell | $0.4554 | Sell |
| MA 50 | $0.4245 | Buy | $0.4421 | Sell |
| MA 100 | $0.4228 | Buy | $0.4814 | Sell |
| MA 200 | $0.5573 | Sell | $0.7373 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.61 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -111.24 | Sell |
| Williams %R (14) | -88.46 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -13.97 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 11.54 | Buy |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 30.35 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 0.44 | Sell |
| ADX (14) | 9.15 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 50.
The moving-average backdrop shows SMA50 at $0.4245 and SMA200 at $0.5573, placing the price near the near-term support and below a longer-term average. The 30-day range extends from $0.3033 to $0.5955, with a defined support at $0.415 and resistance at $0.514.
Annualized volatility stands at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.272 | $0.425 | $0.5032 | 0% | Neutral | |
| $0.2691 | $0.3678 | $0.5431 | -13% | Neutral | |
| $0.2917 | $0.4224 | $0.6632 | -1% | Neutral | |
| $0.3505 | $0.5332 | $0.8776 | +25% | Bullish | |
| $0.3434 | $0.5461 | $0.9347 | +29% | Bullish | |
| $0.3585 | $0.5944 | $1.05 | +40% | Bullish | |
| $0.3295 | $0.5684 | $1.04 | +34% | Bullish | |
| $0.2654 | $0.4754 | $0.8904 | +12% | Neutral | |
| $0.2872 | $0.5339 | $1.02 | +26% | Bullish | |
| $0.3183 | $0.6133 | $1.20 | +44% | Bullish | |
| $0.3631 | $0.8068 | $1.74 | +90% | Bullish | |
| $0.7482 | $1.66 | $3.82 | +291% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.272 | $0.425 | $0.5359 | +0.00% |
| August 2026 | $0.35 | $0.4229 | $0.5317 | -0.49% |
| September 2026 | $0.3266 | $0.40 | $0.5131 | -5.41% |
| October 2026 | $0.3297 | $0.4086 | $0.5329 | +2.15% |
| November 2026 | $0.3246 | $0.4063 | $0.5373 | -0.56% |
| December 2026 | $0.2974 | $0.3757 | $0.5032 | -7.54% |
Click any year to see its month-by-month GTBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The GTBP price prediction for 2026 points to an average of $0.425 (low $0.272, high $0.5032) — a potential gain of 0% on today's $0.425. Price action looks broadly range-bound.
In 2027, GTBP is projected to trade between $0.2691 and $0.5431, averaging $0.3678 — a potential decline of -13% from today's $0.425. That is -13% versus the projected 2026 average. A consolidation phase looks the most probable path here.
GT Biopharma, Inc.'s 2028 outlook centres on $0.4224, within a $0.2917 to $0.6632 range. That is up +15% on the projected 2027 average. That marks a -1% change versus current levels. Price action looks broadly range-bound.
By 2029, GTBP could reach as high as $0.8776, with a base case around $0.5332 and support toward $0.3505 — roughly +25% from $0.425. Buyers look set to stay in control over this stretch.
Expect GTBP to range from $0.3434 to $0.9347 through 2030. The $0.5461 average target implies a +29% move from current prices. That is up +2% on the projected 2029 average. Momentum favours further upside here.
The GTBP price prediction for 2031 points to an average of $0.5944 (low $0.3585, high $1.05) — a potential gain of +40% on today's $0.425. Buyers look set to stay in control over this stretch.
In 2032, GTBP is projected to trade between $0.3295 and $1.04, averaging $0.5684 — a potential gain of +34% from today's $0.425. That is -4% versus the projected 2031 average. Momentum favours further upside here.
GT Biopharma, Inc.'s 2033 outlook centres on $0.4754, within a $0.2654 to $0.8904 range. That is -16% versus the projected 2032 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2034, GTBP could reach as high as $1.02, with a base case around $0.5339 and support toward $0.2872 — roughly +26% from $0.425. Momentum favours further upside here.
Expect GTBP to range from $0.3183 to $1.20 through 2035. The $0.6133 average target implies a +44% move from current prices. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The GTBP price prediction for 2040 points to an average of $0.8068 (low $0.3631, high $1.74) — a potential gain of +90% on today's $0.425. Momentum favours further upside here.
In 2050, GTBP is projected to trade between $0.7482 and $3.82, averaging $1.66 — a potential gain of +291% from today's $0.425. That is up +106% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GTBP today (≈ 2,352.941176 GTBP) could be worth
$3,912.4
+$2,912.4 (+291%) by 2050 · US Dollar
Based on the average projected GTBP price of $1.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GTBPwould be worth at today's price.
$1,000 invested in GTBP on Jul 10, 2025 (≈ 436.68123 GTBP) would be worth
$185.59
-$814.41 (-81.4%) today · 0.19× · US Dollar
Based on a GTBP entry price of $2.29 vs. today's $0.425.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.472 | $900.42 | -10.0% |
| 1 month ago | $0.415 | $1,024.1 | +2.4% |
| 3 months ago | $0.369 | $1,151.76 | +15.2% |
| 6 months ago | $0.73 | $582.19 | -41.8% |
| 1 year ago | $2.29 | $185.59 | -81.4% |
| All time (5.0y) ago | $442.2 | $0.96 | -99.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GTBP forecast.
Our base-case forecast reaches $0.85 around 2050.
Implied market cap at $0.85: $30.65M
The multi-year forecast points to a bullish phase beginning in later years, with several years showing notable upside.
Key milestones include 2029 avg $0.5324 with ROI 25.3%, 2030 avg $0.5475 ROI 28.8%, 2031 avg $0.5942 ROI 39.8%, and 2032 avg $0.5676 ROI 33.6%.
Tap a question to reveal the answer.
The forecast shows the 2030 average price of $0.5475 with ROI 28.8%, with a min of $0.3442 and a max of $0.937.
Forecasts indicate bullish sentiment in 2029–2032 onward, with 2029 avg $0.5324 (ROI 25.3%), 2030 avg $0.5475 (ROI 28.8%), 2031 avg $0.5942 (ROI 39.8%), and 2032 avg $0.5676 (ROI 33.6%). These are estimates, not guarantees.
The forecast maximums include $1.20 in 2035 and $1.73 in 2040, with a long-run max of $3.82 in 2050.
2026 shows min $0.272, avg $0.425, max $0.5023 with ROI 0 and sentiment NEUTRAL.
Current price is $0.425 and market cap is $15.33M.
GT Biopharma, Inc. Community Discussion
0Share your GT Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.